Skip to main content

4 Result(s)

within G Mulligan Remove this filter

and

  1. No Access

    Article

    RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response

    Chromosomal region 1p22 is deleted in ⩾20% of multiple myeloma (MM) patients, suggesting the presence of an unidentified tumor suppressor. Using high-resolution genomic profiling, we delimit a 58 kb minimal de...

    I J F Hofman, M van Duin, E De Bruyne, L Fancello, G Mulligan, E Geerdens… in Leukemia (2017)

  2. Article

    Erratum: A gene expression signature for high-risk multiple myeloma

    Correction to: Leukemia (2012) 26, 2406–2413; doi:10.1038/leu.2012.127 Since the publication of this article, the authors have discovered an error in the script for calculating the IFM-15 risk scores. In their...

    R Kuiper, A Broyl, Y de Knegt, M H van Vliet, E H van Beers, B van der Holt… in Leukemia (2014)

    Download PDF (862 KB) View Article

  3. No Access

    Article

    A gene expression signature for high-risk multiple myeloma

    There is a strong need to better predict the survival of patients with newly diagnosed multiple myeloma (MM). As gene expression profiles (GEPs) reflect the biology of MM in individual patients, we built a pro...

    R Kuiper, A Broyl, Y de Knegt, M H van Vliet, E H van Beers, B van der Holt… in Leukemia (2012)

  4. No Access

    Article

    Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

    Events mediating transformation from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are unknown. We analyzed gene expression data sets generated on the Aff...

    W-J Chng, G F Huang, T H Chung, S B Ng, N Gonzalez-Paz, T Troska-Price… in Leukemia (2011)